Results 251 to 260 of about 12,736,036 (293)

Recombinant factor VIIa

Emergency Medicine, 2004
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire   +2 more sources

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Journal of Thrombosis and Haemostasis, 2014
Vatreptacog alfa, a recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions and 99% identity to native FVIIa, was developed to improve the treatment of hemophilic patients with inhibitors.
S. Lentz, S. Ehrenforth, F. Abdul Karim, T. Matsushita, K. Weldingh, J. Windyga, J. Mahlangu, For the Adept™2 Investigators   +7 more
exaly   +2 more sources

Recombinant Factor VIIa

AACN Advanced Critical Care, 2007
Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest.
openaire   +1 more source

Neutral macrocyclic factor VIIa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2017
Factor VIIa (FVIIa) inhibitors have shown strong antithrombotic efficacy in preclinical thrombosis models with limited bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful due to the requirement of a basic P1 group to interact with Asp189 in the S1 binding pocket, limiting their membrane permeability ...
Nicholas R, Wurtz, Brandon L, Parkhurst, Indawati, DeLucca, Peter W, Glunz, Wen, Jiang, Xiaojun, Zhang, Daniel L, Cheney, Jeffrey M, Bozarth, Alan R, Rendina, Anzhi, Wei, Tim, Harper, Joseph M, Luettgen, Yiming, Wu, Pancras C, Wong, Dietmar A, Seiffert, Ruth R, Wexler, E Scott, Priestley   +16 more
openaire   +2 more sources

Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors

Bioorganic & Medicinal Chemistry Letters, 2013
Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor VIIa inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P' binding interactions.
Peter W, Glunz, Xiaojun, Zhang, Yan, Zou, Indawati, Delucca, Alexandra H, Nirschl, Xuhong, Cheng, Carolyn A, Weigelt, Daniel L, Cheney, Anzhi, Wei, Rushith, Anumula, Joseph M, Luettgen, Alan R, Rendina, Mark, Harpel, Gang, Luo, Robert, Knabb, Pancras C, Wong, Ruth R, Wexler, E Scott, Priestley   +17 more
openaire   +2 more sources

Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation

Clinical Chemistry and Laboratory Medicine, 2017
L. Spiezia, E. Campello, F. Valle, B. Woodhams, P. Simioni   +4 more
semanticscholar   +1 more source

Tissue factor (:Factor VIIa) in the heart and vasculature: More than an envelope.

Thrombosis Research, 2018
E. D'Alessandro, J. Posma, H. Spronk, H. Cate   +3 more
semanticscholar   +1 more source

The Judicious Use of Recombinant Factor VIIa

Seminars in Thrombosis and Hemostasis, 2016
L. Goodnough, J. Levy
semanticscholar   +1 more source

Comparison of Fresh‐Frozen Plasma, Four‐Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study

Pharmacotherapy, 2016
Jennifer O. Kwon, R. MacLaren
semanticscholar   +1 more source

Recombinant factor VIIa

Reactions Weekly, 2018
  +5 more sources